Literature DB >> 21412935

HIV sexual transmission and microbicides.

Kevin K Ariën1, Vicky Jespers, Guido Vanham.   

Abstract

Pathogens often rely on the contacts between hosts for transmission. Most viruses have adapted their transmission mechanisms to defined behaviours of their host(s) and have learned to exploit these for their own propagation. Some viruses, such as HIV, the human papillomavirus (HPV), HSV-2 and HCV, cause sexually transmitted infections (STIs). Understanding the transmission of particular viral variants and comprehending the early adaptation and evolution is fundamental to eventually inhibiting sexual transmission of HIV. Here, we review the current understanding of the mechanisms of sexual transmission and the biology of the transmitted HIV. Next, we present a timely overview of candidate microbicides, including past, ongoing and future clinical trials of HIV topical microbicides.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21412935     DOI: 10.1002/rmv.684

Source DB:  PubMed          Journal:  Rev Med Virol        ISSN: 1052-9276            Impact factor:   6.989


  19 in total

1.  Polymeric nanoparticles affect the intracellular delivery, antiretroviral activity and cytotoxicity of the microbicide drug candidate dapivirine.

Authors:  José das Neves; Johan Michiels; Kevin K Ariën; Guido Vanham; Mansoor Amiji; Maria Fernanda Bahia; Bruno Sarmento
Journal:  Pharm Res       Date:  2011-11-10       Impact factor: 4.200

2.  In vitro activities of candidate microbicides against cell-associated HIV.

Authors:  Philippe Selhorst; Katrijn Grupping; Thomas Bourlet; Olivier Delézay; Kevin K Ariën; Guido Vanham
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

Review 3.  Interactions between HIV-1 and mucosal cells in the female reproductive tract.

Authors:  Ruizhong Shen; Holly E Richter; Phillip D Smith
Journal:  Am J Reprod Immunol       Date:  2014-04-01       Impact factor: 3.886

4.  Preclinical evaluation of the HIV-1 fusion inhibitor L'644 as a potential candidate microbicide.

Authors:  Sarah Harman; Carolina Herrera; Naomi Armanasco; Jeremy Nuttall; Robin J Shattock
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

Review 5.  Mucosal transmission of human immunodeficiency virus.

Authors:  Denis M Tebit; Nicaise Ndembi; Aaron Weinberg; Miguel E Quiñones-Mateu
Journal:  Curr HIV Res       Date:  2012-01-01       Impact factor: 1.581

6.  Tetrahydrocurcumin-loaded vaginal nanomicrobicide for prophylaxis of HIV/AIDS: in silico study, formulation development, and in vitro evaluation.

Authors:  Amit Mirani; Harish Kundaikar; Shilpa Velhal; Vainav Patel; Atmaram Bandivdekar; Mariam Degani; Vandana Patravale
Journal:  Drug Deliv Transl Res       Date:  2019-08       Impact factor: 4.617

7.  MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency.

Authors:  Katrijn Grupping; Philippe Selhorst; Johan Michiels; Katleen Vereecken; Leo Heyndrickx; Pascal Kessler; Guido Vanham; Loïc Martin; Kevin K Ariën
Journal:  Retrovirology       Date:  2012-05-02       Impact factor: 4.602

8.  Anti-HIV-1 activity of a new scorpion venom peptide derivative Kn2-7.

Authors:  Yaoqing Chen; Luyang Cao; Maohua Zhong; Yan Zhang; Chen Han; Qiaoli Li; Jingyi Yang; Dihan Zhou; Wei Shi; Benxia He; Fang Liu; Jie Yu; Ying Sun; Yuan Cao; Yaoming Li; Wenxin Li; Deying Guo; Zhijian Cao; Huimin Yan
Journal:  PLoS One       Date:  2012-04-19       Impact factor: 3.240

9.  M48U1 CD4 mimetic has a sustained inhibitory effect on cell-associated HIV-1 by attenuating virion infectivity through gp120 shedding.

Authors:  Philippe Selhorst; Katrijn Grupping; Tommy Tong; Ema T Crooks; Loïc Martin; Guido Vanham; James M Binley; Kevin K Ariën
Journal:  Retrovirology       Date:  2013-02-01       Impact factor: 4.602

10.  The lantibiotic peptide labyrinthopeptin A1 demonstrates broad anti-HIV and anti-HSV activity with potential for microbicidal applications.

Authors:  Geoffrey Férir; Mariya I Petrova; Graciela Andrei; Dana Huskens; Bart Hoorelbeke; Robert Snoeck; Jos Vanderleyden; Jan Balzarini; Stefan Bartoschek; Mark Brönstrup; Roderich D Süssmuth; Dominique Schols
Journal:  PLoS One       Date:  2013-05-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.